<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="164228">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00960050</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000651820</org_study_id>
    <secondary_id>VU-VICC-PED-0937</secondary_id>
    <nct_id>NCT00960050</nct_id>
  </id_info>
  <brief_title>Methemoglobinemia in Patients With Childhood Hematologic Cancer or Aplastic Anemia Treated With Dapsone</brief_title>
  <official_title>Dapsone Induced Methemoglobinemia Study (DIMS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt-Ingram Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Gathering information about patients with childhood hematologic cancer or
      aplastic anemia treated with dapsone may help doctors learn more about risk factors for
      developing methemoglobinemia.

      PURPOSE: This phase I trial is studying methemoglobinemia in patients with childhood
      hematologic cancer or aplastic anemia treated with dapsone.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  Determine host-related risk factors for developing symptomatic methemoglobinemia in
           patients with pediatric hematologic malignancies or aplastic anemia who received
           dapsone prophylaxis for pneumocystis carinii.

        -  Determine whether a deficiency in cytochrome b5 reductase is a risk factor for
           symptomatic methemoglobinemia in a subset of these patients.

      Secondary

        -  Collect a genomic DNA specimen from a subset of patients for whom enzyme testing is
           being conducted to store for future analyses of variations in the genes responsible for
           cytochrome b5 reductase.

      OUTLINE: Patients' medical records are reviewed for possible risk factors (e.g., age, sex,
      and body mass index) for developing symptomatic methemoglobinemia.

      A subset of patients undergo blood sample collection for analysis of cytochrome b5 reductase
      levels. DNA samples are also collected from these patients for future genetic polymorphism
      studies.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>June 2009</start_date>
  <primary_completion_date type="Anticipated">May 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <primary_outcome>
    <measure>Age, sex, and body mass index as host-related risk factors for developing symptomatic methemoglobinemia</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Cytochrome b5 reductase levels</measure>
  </primary_outcome>
  <enrollment type="Anticipated">173</enrollment>
  <condition>Leukemia</condition>
  <condition>Lymphoma</condition>
  <condition>Methemoglobinemia</condition>
  <condition>Nonmalignant Neoplasm</condition>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>polymorphism analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>medical chart review</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>assessment of therapy complications</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Diagnosis of hematologic malignancy or aplastic anemia within the past 15 years at
             the Division of Pediatric Hematology/Oncology at Vanderbilt University

          -  Previously treated with dapsone as prophylaxis for pneumocystis carinii

          -  May or may not have symptomatic methemoglobinemia

        PATIENT CHARACTERISTICS:

          -  Not specified

        PRIOR CONCURRENT THERAPY:

          -  Not specified
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>22 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adam J. Esbenshade, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt-Ingram Cancer Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kathleen M. Von Wahlde</last_name>
    <affiliation>Vanderbilt-Ingram Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vanderbilt-Ingram Cancer Center - Cool Springs</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37064</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt-Ingram Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232-6838</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2010</verification_date>
  <lastchanged_date>May 28, 2010</lastchanged_date>
  <firstreceived_date>August 14, 2009</firstreceived_date>
  <responsible_party>
    <name_title>Adam J. Esbenshade</name_title>
    <organization>Vanderbilt-Ingram Cancer Center</organization>
  </responsible_party>
  <keyword>methemoglobinemia</keyword>
  <keyword>aplastic anemia</keyword>
  <keyword>childhood acute lymphoblastic leukemia</keyword>
  <keyword>childhood acute myeloid leukemia/other myeloid malignancies</keyword>
  <keyword>childhood chronic myelogenous leukemia</keyword>
  <keyword>juvenile myelomonocytic leukemia</keyword>
  <keyword>childhood Hodgkin lymphoma</keyword>
  <keyword>childhood large cell lymphoma</keyword>
  <keyword>childhood lymphoblastic lymphoma</keyword>
  <keyword>childhood small noncleaved cell lymphoma</keyword>
  <keyword>childhood anaplastic large cell lymphoma</keyword>
  <keyword>childhood diffuse large cell lymphoma</keyword>
  <keyword>childhood grade III lymphomatoid granulomatosis</keyword>
  <keyword>childhood immunoblastic large cell lymphoma</keyword>
  <keyword>childhood nasal type extranodal NK/T-cell lymphoma</keyword>
  <keyword>childhood myelodysplastic syndromes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Methemoglobinemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dapsone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
